Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

show abstract

“…32 Recently updated data as of 2016 showed that a little over one-half the cohort appeared susceptible to either infection. 33…”

Section: Resultsmentioning

confidence: 99%

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection

Moorman

Rupp

Gordon

et al. 2018

Infectious Disease Clinics of North America

Self Cite

View full text Add to dashboard Cite

show abstract

“…Because hepatitis patients can be coinfected with multiple types of hepatitis viruses, the simultaneous determination of multiple hepatitis viruses facilitates clinical diagnosis and the choice of an appropriate treatment regimen. Moreover, simultaneous detection can reduce the time and resources used for testing as compared to assaying for each virus separately.…”

Section: Introductionmentioning

confidence: 99%

“…3,6 POC tests have advanced in the technology, a platform using selfpowered electrochromic display with a digital multimeter readout and a smartphone-based POC device were also developed. 7,8 Because hepatitis patients can be coinfected with multiple types of hepatitis viruses, [9][10][11] the simultaneous determination of multiple hepatitis viruses facilitates clinical diagnosis and the choice of an appropriate treatment regimen. Moreover, simultaneous detection can reduce the time and resources used for testing as compared to assaying for each virus separately.…”

mentioning

confidence: 99%

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Kweon

Lim

Kim

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Background Although immunoassays play a major role in the detection of hepatitis viruses, there is a need for a point‐of‐care (POC) test. We evaluated the EuDx‐HE (A,B,C) kit (EUDIPIA, Cheongju, Korea), which detects anti‐hepatitis A virus (HAV) immunoglobulin M (IgM), hepatitis B virus surface antigen (HBsAg), and anti‐hepatitis C virus (HCV) immunoglobulin G (IgG) simultaneously using an immunochromatographic method within 15 minutes. Methods A total of 1581 serum samples including 57, 477, and 451 samples positive for anti‐HAV IgM, HBsAg, and anti‐HBV IgG, respectively, were analyzed. We investigated the diagnostic accuracy of the EuDx‐HE (A,B,C) kit by comparison with SD BIOLINE POC kits (Abbott, Chicago, IL) using Architect immunoassays as a reference method. Results For anti‐HAV IgM and HBsAg detection, the EuDx‐HE (A,B,C) kit showed a higher sensitivity and a slightly lower specificity than the SD BIOLINE kit. For anti‐HCV IgG detection, the EuDx‐HE (A,B,C) kit had a higher sensitivity and a higher specificity than the SD BIOLINE kit. The agreement for positivity between the POC tests was >89.47%, with κ values of 0.844, 0.941, and 0.943 for HAV, HBV, and HCV, respectively. Conclusion The EuDx‐HE (A,B,C) kit showed an acceptable clinical performance for detecting anti‐HAV IgM, HBsAg, and anti‐HCV.

show abstract

“…9 Data from the US Chronic Hepatitis Cohort Study observed that over 40% of chronic hepatitis B and chronic hepatitis C patients did not have any evidence of documented vaccination or immunity to hepatitis A and hepatitis B. 13,16 In the United States, nearly 100 million adults are affected with nonalcoholic fatty liver disease, 17 and recent studies report increasing burden and disease progression of patients with alcoholic liver disease. 18,19 Yet, few studies have specifically evaluated rates of successful hepatitis A and hepatitis B vaccination in these populations.…”

Section: Introductionmentioning

confidence: 99%

Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease

Wong

Gish

Cheung

et al. 2021

The American Journal of Medicine

View full text Add to dashboard Cite

Need for Increasing Hepatitis A Virus Vaccination Among Patients Infected With Hepatitis B Virus and Hepatitis C Virus

Cited by 9 publications

References 8 publications

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection

Analytical performance of newly developed rapid point‐of‐care test for the simultaneous detection of hepatitis A, B, and C viruses in serum samples

Low Prevalence of Vaccination or Documented Immunity to Hepatitis A and Hepatitis B Viruses Among Individuals with Chronic Liver Disease

Contact Info

Product

Resources

About